



Minerva Neurosciences, Inc.
Investor Relations Department
1601 Trapelo Road
Suite 284
Waltham, MA 02451
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: NERV

Last Trade:	9.10
Trade Time:	1:34 PM ET Jun 27, 2017
Change:	-0.20 (-2.151%)
Day Range	9.10 - 9.30
52-Week Range	6.50 - 14.92
Volume	60,076

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat central nervous system (CNS) diseases. Minerva's proprietary compounds include: MIN-101, which has completed Phase IIb development for schizophrenia; MIN-202 (JNJ-42847922), which has completed Phase IIa and Phase Ib clinical trials for insomnia and MDD, respectively; MIN-117, which has completed Phase IIa development for MDD; and MIN-301, in pre-clinical development for Parkinson's disease. Minerva's common stock is... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jun 22, 2017

[Minerva Announces Completion of Bridging Study to Select Improved Formulation of MIN-101 for Use in Phase 3 Trial for the Treatment of Negative Symptoms in Patients With Schizophrenia](#)

May 31, 2017

[Minerva Announces Amended Agreement for MIN-202 in Insomnia](#)

May 30, 2017

[Minerva Neurosciences to Present at Jefferies 2017 Healthcare Conference on June 6, 2017](#)

May 15, 2017

[Minerva Provides Update on Phase 3 Design and Development Strategy for MIN-101](#)

May 15, 2017

[Minerva Announces Outcome of End-of-Phase 2 Meeting With FDA](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Mar 13, 2017

[Annual Report \(10-K\)](#)

Apr 18, 2017

[Proxy Statement \(DEF 14A\)](#)

May 4, 2017

[Quarterly Report \(10-Q\)](#)

Nov 3, 2016

[Quarterly Report \(10-Q\)](#)

Aug 4, 2016

[Quarterly Report \(10-Q\)](#)